| Literature DB >> 2898699 |
F J Giles1, C R Singer, A G Gray, K L Yong, M Brozovic, S C Davies, I R Grant, A V Hoffbrand, S J Machin, A B Mehta.
Abstract
18 patients with symptomatic essential thrombocythaemia were treated with recombinant alpha interferon (2a or 2b). Subcutaneous dosage regimens, which were well-tolerated, selectively lowered the platelet count and relieved symptoms in all patients, whether previously treated or untreated. Recombinant alpha-interferon may offer a non-leukaemogenic alternative therapy for these patients.Entities:
Mesh：
Substances：
Year: 1988 PMID： 2898699 DOI： 10.1016/s0140-6736(88)90005-0
Source DB: PubMed Journal: Lancet ISSN： 0140-6736 Impact factor: 79.321